Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-04-19
2011-04-19
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S143100, C424S144100, C424S153100, C424S173100, C530S387100, C530S388100, C530S388200, C530S388700, C530S388750
Reexamination Certificate
active
07927595
ABSTRACT:
Methods for modulating HIV-1 fusion cofactor expression by manipulating an accessory molecule on the surface of T cells, such as CD28, are described. The invention encompasses methods for modulating HIV-1 fusion cofactor expression by stimulating or inhibiting one or more intracellular signals which result from ligation of a surface receptor on a T cell which binds a costimulatory molecule. In one embodiment, expression of an HIV-1 fusion cofactor, such as CCR5, is downregulated by stimulating a CD28-associated signal in the T cell.
REFERENCES:
patent: 5561047 (1996-10-01), Shattil
patent: 6129916 (2000-10-01), Chang
patent: 6352694 (2002-03-01), June et al.
patent: 6569997 (2003-05-01), Kwon
patent: 6905680 (2005-06-01), June et al.
patent: 2004/0086528 (2004-05-01), Allaway et al.
patent: WO 95/33823 (1995-12-01), None
Riley et al. J. Virol. 72:8273-8280 1998.
Carroll et al. Immunol. 10:195-202 1998.
Creson et al. J. Virol. 1999; 73(11):9337-9347.
Spina et al. J. Clin. Invest. 1997; 99:1774-1785.
Alkhatib, G. et al. “CC CKR5: A Rantes, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1”Science272:1955-1958 (1996).
Åsjö, B. et al. “A Novel Mode of Human Immunodeficiency Virus Type 1 (HIV-1) Activation: Ligation of CD28 Alone Induces HIV-1 Replication in Naturally Infected Lymphocytes”Journal of Virology67(7):4395-4398 (1993).
Baca, L.M. et al. “Regulation of Interferon-α-Inducible Cellular Genes in Human Immunodeficiency Virus-Infected Monocytes”Journal of Leukocyte Biology55:299-309 (1994).
Baier, M. et al. “HIV Suppression by Interleukin-16”Nature378:563 (1995).
Barker, T.D. et al. “Identification of Multiple and Distinct CD8+T Cell Suppressor Activities”The Journal of Immunology156:4476-4483 (1996).
Beyers, A.D. et al. “Molecular Associations Between the T-Lymphocyte Antigen Receptor Complex and the Surface Antigens CD2, CD4, or CD8 and CD5”Immunology89:2945-2949 (1992).
Brand, D. et al. “Determinants of Human Immunodeficiency Virus Type 1 Entry in the CDR2 Loop of the CD4 Glycoprotein”Journal of Virology69(1):166-171 (1995).
Breitmeyer, J.B. et al. “The T11 (CD2) Molecule is Functionally Linked to the T3/Ti T Cell Receptor in the Majority of T Cells”The Journal of Immunology139:2899 (1987).
Ceuppens, J.L. and Baroja, M.L. “Monoclonal Antibodies to the CD5 Antigen Can Provide the Necessary Second Signal for Activation of Isolated Resting T Cells by Solid-Phase-Bound OKT3”The Journal of Immunology137:1816-1821 (1986).
Choe, H. et al. “The β-Chemokine Receptors CCR3 and CCr5 Facilitate Infection by Primary HIV-1 Isolates”Cell85:1135-1148 (1996).
Cocchi, F. et al. “Identification of Ranted, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+T Cells”Science270:1811-1815 (1995).
Conlon, K. et al. “CD8+and CD45RA+human Peripheral Blood Lymphocytes are Potent Sources of Macrophage Inflammatory Protein 1α, Interleukin-8 and RANTES”Eur. J. Immunol.25:751-756 (1995).
Dean, M. et al. “Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of theCKR5Structural Gene”Science273:1856-1862 (1996).
Deng, H. et al. “Identification of a Major Co-Receptor for Primary Isolates of HIV-1”Nature381:661-666 (1996).
Doranz, B.J. et al. “A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors”Cell85:1149-1158 (1996).
Dragic, T. et al. “HIV-1 Entry Into CD4+Cells is Mediated by the Chemokine Receptor CC-CKR-5”Nature381:667-673 (1996).
Fauci, A.S. “Host Factors and the Pathogenesis of HIV-Induced Disease”Nature384:529-534 (1996).
Feng, Y. et al. “HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor”Science272:872-877 (1996).
Gartner, S. et al. “The Role of Mononuclear Phagocytes in HTLV-III/LAV Infection”Science233:215-219 (1986).
Geppert, T.D. et al “Activation of Human T4 Cells by Cross-Linking Class I MHC Molecules”The Journal of Immunology140:2155-2164 (1988).
Geppert, T.D and Lipsky, P.E. “Activation of T Lyphocytes by Immobilized Monoclonal Antibodies to CD3: Regulator Influences of Monoclonal Antibodies to Additional T Cell Surface Determinants”J. Clin. Invest.81:1497-1505 (1988).
Hansen, J.A. et al. “Monoclonal Antibodies Identifying a Novel T-Cell Antigen and la Antigens of Human Lymphocytes”Immunogenetics10:247-260 (1980).
June, C.H. et al. “The B7 and CD28 Receptor Families”Immunology Today15(7):321-331 (1994).
June, C.H. et al. “T-Cell Proliferation Involving the CD28 Pathway Is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression”Molecular and Cellular Biology7(12):4472-4481 (1987).
Kabat, D. et al. “Differences in CD4 Dependence for Infectivity of Laboratory-Adapted and Primary Patient Isolates of Human Immunodeficiency Virus Type 1”Journal of Virology68(4):2570-2577 (1994).
Kinter, A.L. et al. “Interleukin 2 Induces CD8+T Cell-Mediated Suppression of Human Immunodeficiency Virus Replication in CD4+T Cells and this Effect Overrides Its Ability to Stimulated Virus Expression”Proc. Natl. Acad. Sci. USA92:10985-10989 (1995).
Kollmann, T. R. et al. “Inhibition of Acute in vivo Human Immunodeficiency Virus Infection by 7 Human Interleukin 10 Treatment of SCID Mice Implanted with Human Fetal Thymus and Liver”Proc. Natl. Acad. Sci. USA93:3126-3131 (1996).
Lai, J-H and Tan, T-H. “CD28 Signaling Causes a sustained Down-Regulation of IκBα Which Be Prevented by the Immunosuppressant Rapamycin”The Journal of Biological Chemistry269(48):30077-30080 (1994).
Ledbetter, J.A. et al. “Antibodies to Tp67 and Tp44 Augment and Sustain Proliferative Responses of Activated T Cells”The Journal of Immunology135(4):2331-2336 (1985).
Ledbetter, J.A. et al. “An Immunoglobulin Light Chain Dimer with CD4 Antigen Specificity”Mol. Immunol.24:1255-1261 (1987).
Ledbetter, J.A. et al. “Role of CD2 Cross-Linking in Cytoplasmic Calcium Responses and T Cell Activation”Eur. J. Immunol.18:1601-1608 (1988).
Ledbetter, J.A. et al. “Signal Transduction Through CD4 Receptors: Stimulatory vs. Inhibitory Activity is Regulated by CD4 Proximity to the CD3/T Cell Receptor”Eur. J. Immunol.18:525-532(1988).
Levine, B.L. et al. “Antiviral Effect and Ex Vivo CD4+T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation”Science272:1939-1943 (1996).
Levine, B.L. et al. “CD28 Ligands CD80 (B7-1) and CD86 (B7-2) Induce Long-Term Autocrine Growth of CD4+T Cells and Induce Similar Patterns of Cytokine Secretion in vitro”International Immunology7(6):891-904 (1995).
Liu, R. et al. “Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection”Cell86:367-377 (1996).
Loetscher, P. et al. “Interleukin-2 Regulates CC Chemokine Receptor Expression and Chemotactic Responsiveness in T Lymphocytes”J. Exp. Med.184:569-577 (1996).
Los, M. et al. “Inhibition of Activation of Transcription Factor AP-1 by CD28 Signalling in Human T-Cells”Biochem. J.302:119-123 (1994).
Mackewicz, C.E. et al. “CD8+T Cells Suppress Human Immunodeficiency Virus Replication by Inhibiting Viral Transcription”Proc. Natl. Acad. Sci. USA92:2308-2312 (1995).
Martin, P.J. et al. “A New Human T-Cell Differentiation Antigen: Unexpected Expression on Chronic Lymphocytic Leukemia Cells”Immunogenetics11:429-439 (1980).
Mascola, J.R. et al. “Two Antigenically Distinct Subtypes of Human Immunodeficiency Virus Type 1: Viral Genotype Predicts Neutralization Serotype”The Journal of Infectious Diseas
Carroll Richard G.
June Carl H.
Levine Bruce L.
Riley James L.
St. Louis Daniel C.
Churilla Albert
Gambel Phillip
Hemby, Jr. Joseph K.
The United States of America as represented by the Secretary of
Yang Ning
LandOfFree
Methods for downregulating CCR5 in T cells with anti-CD3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for downregulating CCR5 in T cells with anti-CD3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for downregulating CCR5 in T cells with anti-CD3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2686172